Ionis wins FDA clearance for Alexander disease drug, company's first solo neurology approval

Part of story

Ionis Pharmaceuticals wins FDA approval for first Alexander disease treatment, priced at $285,000 per dose

The FDA approved Zanvastro, an antisense oligonucleotide therapy from Ionis Pharmaceuticals, as the first targeted treatment for Alexander disease, a rare and deadly genetic neurological disorder affecting adults and children. The company priced the injectable drug at $285,000 per dose.

Sep 3, 20265 sourcesFDA drug approval Drug pricing

Ionis Pharmaceuticals wins FDA approval for first Alexander disease treatment, priced at $285,000 per dose

Other sources for this story

Statnews

Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder

Biospace

FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease

Reuters

Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose | Reuters

Fiercepharma

Ionis wins FDA clearance for Alexander disease drug, company's first solo neurology approval

Part of story

Ionis Pharmaceuticals wins FDA approval for first Alexander disease treatment, priced at $285,000 per dose

Other sources for this story

Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder

FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease

Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose | Reuters

Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline

Ionis wins FDA clearance for Alexander disease drug, company's first solo neurology approval

Part of story

Ionis Pharmaceuticals wins FDA approval for first Alexander disease treatment, priced at $285,000 per dose

Other sources for this story

Ionis wins FDA approval for first drug for Alexander disease, a rare and deadly neurological disorder

FDA approves Ionis’ antisense drug as first targeted therapy for Alexander disease

Ionis Pharma prices first FDA-approved treatment for Alexander disease at $285,000 per dose | Reuters

Ionis’ ‘breakthrough’ Alexander disease approval establishes pillar of rare disease pipeline